A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Trial Profile

A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Status changed from recruiting to discontinued, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results assessing the maximum tolerated dose of Carfilzomib in combination with melphalan and prednisone in untreated elderly multiple myeloma patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 23 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top